Hepatitis B vaccination: long-term follow-up of the immune response of preterm infants and comparison of two vaccination protocols |
| |
Authors: | Linder N Vishne T H Levin E Handsher R Fink-Kremer I Waldman D Levine A Ashkenazi S Sirota L |
| |
Affiliation: | (1) Dept. of Neonatology, Schneider Children's Medical Center of Israel, 14 Kaplan Str., Petah Tiqva 49202, Israel; Phone: (+97/23) 9253753, Fax: (+97/23) 5340934, e-mail: lindern@netvision.net.il, IL;(2) Dept. of Neonatology, The Chaim Sheba Medical Center, Tel Hashomer, Israel, IL;(3) Central Virology Laboratory, The Chaim Sheba Medical Center, Israel, IL |
| |
Abstract: | Background: We conducted a 3-year follow-up study of long-term antibody persistence following vaccination of low-risk preterm infants with recombinant hepatitis B vaccine (HBV). Two three-dose protocols were compared: vaccination beginning within 24 h of birth to initial vaccination delayed until a weight of 2,000 g was reached. Patients and Methods: The study population included 136 children, divided into three groups: children born prematurely (≤ 35 weeks, n = 57), children born at term (≥ 37 weeks, n = 39), both groups receiving the first dose of HBV within 24 h of birth, and children born prematurely (≤ 35 weeks, n = 40), who received the first dose of HBV when a weight of 2,000 g was reached. All infants received the second hepatitis vaccination 1 month after the first, and the third dose 6 months after the first. Hepatitis B surface antibody (AntiHBs) was measured at an age of 3–3.5 years (at least 2.5 years after completion of the three-dose HBV series). An AntiHBs level of ≥ 10 IU/l was considered positive. Results: At 3–3.5 years of age, a higher percentage of the premature-delayed vaccination group had a positive AntiHBs level (92.5%) compared to both the premature (54.5%, p < 0.001) and full-term groups (71.8%, p < 0.05) vaccinated soon after birth. The premature-delayed vaccination group also had a significantly higher geometric mean concentration (GMC) (119 vs 14.2 IU/l, p < 0.001 and 119 vs 32.7 IU/l, p < 0.005, respectively). Conclusion: Delaying vaccination of premature infants against hepatitis B until a weight of 2,000 g was reached resulted in both a significantly higher percentage of children with positive antibody levels and a significantly higher GMC at 3–3.5 years of age as compared to early-vaccinated preterm and full-term infants. The known short-term advantage of delayed vaccination of preterm infants was shown to persist for at least the first 3 years of life. Received: July 12, 2001 · Revision accepted: January 8, 2002 |
| |
Keywords: | Preterm Hepatitis B immunization Antibody decay |
本文献已被 PubMed SpringerLink 等数据库收录! |
|